Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996084 · ClinicalTrials.gov registry record
MS PATHS Normative Sub-Study
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 246
- Enrollment target
NCT02996084 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 246 participants.
The verdict
NCT02996084 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the normative range of brain volume and brain volume change in healthy control (HC) participants whose age, race, and gender distribution is approximately matched to the age, race, and gender distribution of patients with Multiple Sclerosis (MS) enrolled in Study 888MS001. The secondary objective is to use the results of the primary endpoint to ensure consistency of brain volume measurements across MS PATHS centers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996084
The ClinicalTrials.gov registry entry for NCT02996084 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02996084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02996084 about?
NCT02996084 is a clinical study titled "MS PATHS Normative Sub-Study". The primary objective of this study is to determine the normative range of brain volume and brain volume change in healthy control (HC) participants whose age, race, and gender distribution is approximately matched to the age, race, and gender distribution of patients with Multiple Sclerosis (MS) en...
What is the current status of trial NCT02996084?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2017-12-12. Estimated completion is 2022-12-31.
Who is sponsoring clinical trial NCT02996084?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.